PMID- 32785949
OWN - NLM
STAT- MEDLINE
DCOM- 20210104
LR  - 20210104
IS  - 1097-4598 (Electronic)
IS  - 0148-639X (Linking)
VI  - 62
IP  - 5
DP  - 2020 Nov
TI  - Efficacy and safety of high infusion rate IVIG in CIDP.
PG  - 637-641
LID - 10.1002/mus.27044 [doi]
AB  - BACKGROUND: We aimed to determine the safety and tolerance of higher rates of 
      infusion of intravenous immunoglobulin (IVIG) in patients with chronic 
      inflammatory demyelinating polyradiculoneuropathy (CIDP). METHODS: Patients began 
      infusions with 10% IVIG at the standard rate of 0.08 mL/kg/min. If tolerated, 
      infusion rates were incrementally increased to 0.14 mL/kg/min. We considered the 
      frequency of infusions with adverse events (AEs) as the primary outcome. RESULTS: 
      Nineteen of 25 patients safely tolerated the maximum rate of 0.14 mL/kg/min. We 
      observed 25 treatment-related AEs (TAEs) over 13 infusions at standard or 
      transitional rates, across seven patients. We observed no TAEs associated with 
      the maximum infusion rate. CONCLUSIONS: We found that 10% IVIG can be safely 
      administered at a high infusion rate (0.14 ml/kg/min) in most CIDP patients, 
      reducing the treatment time and burden on healthcare resources.
CI  - (c) 2020 Wiley Periodicals LLC.
FAU - Jiang, Yue
AU  - Jiang Y
AD  - Ellen and Martin Prosserman Centre for Neuromuscular Diseases, University Health 
      Network, Toronto, Ontario, Canada.
FAU - Mendoza, Meg
AU  - Mendoza M
AD  - Ellen and Martin Prosserman Centre for Neuromuscular Diseases, University Health 
      Network, Toronto, Ontario, Canada.
FAU - Sarpong, Evelyn
AU  - Sarpong E
AD  - Ellen and Martin Prosserman Centre for Neuromuscular Diseases, University Health 
      Network, Toronto, Ontario, Canada.
FAU - Mannan, Shabber
AU  - Mannan S
FAU - Ng, Eduardo
AU  - Ng E
AD  - Ellen and Martin Prosserman Centre for Neuromuscular Diseases, University Health 
      Network, Toronto, Ontario, Canada.
FAU - Katzberg, Hans
AU  - Katzberg H
AD  - Ellen and Martin Prosserman Centre for Neuromuscular Diseases, University Health 
      Network, Toronto, Ontario, Canada.
FAU - Bril, Vera
AU  - Bril V
AD  - Ellen and Martin Prosserman Centre for Neuromuscular Diseases, University Health 
      Network, Toronto, Ontario, Canada.
FAU - Barnett, Carolina
AU  - Barnett C
AUID- ORCID: 0000-0001-5546-0221
AD  - Ellen and Martin Prosserman Centre for Neuromuscular Diseases, University Health 
      Network, Toronto, Ontario, Canada.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200911
PL  - United States
TA  - Muscle Nerve
JT  - Muscle & nerve
JID - 7803146
RN  - 0 (Immunoglobulins, Intravenous)
SB  - IM
MH  - Aged
MH  - Female
MH  - Humans
MH  - Immunoglobulins, Intravenous/*administration & dosage/*adverse effects
MH  - Infusions, Intravenous/adverse effects/methods
MH  - Male
MH  - Middle Aged
MH  - Patient Satisfaction
MH  - Polyradiculoneuropathy, Chronic Inflammatory Demyelinating/*drug therapy
MH  - Treatment Outcome
OTO - NOTNLM
OT  - CIDP
OT  - IVIG
OT  - infusion rates
OT  - treatment satisfaction
EDAT- 2020/08/14 06:00
MHDA- 2021/01/05 06:00
CRDT- 2020/08/14 06:00
PHST- 2020/01/10 00:00 [received]
PHST- 2020/07/31 00:00 [revised]
PHST- 2020/08/07 00:00 [accepted]
PHST- 2020/08/14 06:00 [pubmed]
PHST- 2021/01/05 06:00 [medline]
PHST- 2020/08/14 06:00 [entrez]
AID - 10.1002/mus.27044 [doi]
PST - ppublish
SO  - Muscle Nerve. 2020 Nov;62(5):637-641. doi: 10.1002/mus.27044. Epub 2020 Sep 11.